Vaccitech plc (VACC)
|Net Income (ttm)||n/a|
|Trading Day||July 26|
|Day's Range||14.61 - 15.27|
|52-Week Range||12.25 - 17.99|
Arbutus Biopharma Corporation (NASDAQ: ABUS) and Vaccitech plc (NASDAQ: VACC) have collaborated to evaluate combination treatment for chronic hepatitis B virus who are already receiving standard-of-care...
OXFORD, United Kingdom, June 14, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics an...
OXFORD, United Kingdom, May 04, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and...
Here's how VACC stock has performed thus far following the company's highly anticipated IPO in the market today. The post VACC Stock IPO: 7 Things to Know as Vaccitech Starts Trading Today appeared firs...
OXFORD, United Kingdom, April 29, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (“Vaccitech”) (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immuno...
Biotech startup Vaccitech Plc, which owns the technology behind the COVID-19 vaccine developed by Oxford University and AstraZeneca Plc, filed for a U.S. initial public offering on Friday.
Vaccitech plc has filed to go public with an IPO on the NASDAQ.
AstraZeneca vaccine co-inventors' float on US market is a blow to the UK - but it's not all bad news
Vaccitech's decision to float in the US is a blow to the UK but its success reveals some important and reassuring developments.
Sarah Gilbert, Adrian Hill and Oxford University to get windfalls when Covid vaccine firm Vaccitech goes public
Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. We use our proprietary platform to develop product candidates that stimulate powerful, targeted immune responses against pathogens and tumor cells. We design our product candidates to stimulate immune responses that are robust, highly specific, and are differentiated by the magnitude of the T cell populations induced, which exhibit critical f... [Read more...]
|IPO Date |
Apr 30, 2021
|Stock Exchange |
|Ticker Symbol |
In 2020, Vaccitech's revenue was $4.82 million, a decrease of -29.58% compared to the previous year's $6.85 million. Losses were -$17.71 million, -14.59% less than in 2019.
The average 12-month stock price forecast for Vaccitech is 24.50, which is an increase of 61.40% from the latest price.